AstraZeneca and Schering have inked an agreement to collaborate on development and licensing of Selective Glucocorticoid Receptor Agonists (SEGRAs), potentially a new class of anti-inflammatory drugs. The two companies will jointly research and develop several SEGRAs that Schering has identified, through the end of Phase I clinical trials. After that, AstraZeneca will have an exclusive worldwide license to develop and market compounds for rheumatoid and respiratory diseases, while Schering will have the rights to all other uses of the drugs.
- read this press release for more